Kolexia
Feugier Pierre Médecine interne
Feugier Pierre
Médecine interne
Hôpital Brabois
Vandoeuvre-lès-Nancy, France
384 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Leucémies Leucémie chronique lymphocytaire à cellules B Lymphome B Leucémie lymphoïde Lymphome folliculaire Lymphome B diffus à grandes cellules Lymphome à cellules du manteau Maladie de Hodgkin

Collaborateurs

Voir plus
Thieblemont Catherine
Thieblemont Catherine
Hôpital Saint-Louis, Paris, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Tilly Herve
Tilly Herve
Centre Henri-Becquerel, Rouen, France

Industries

Voir plus
Janssen
20 collaboration(s)
Dernière en 2023
AstraZeneca
13 collaboration(s)
Dernière en 2023
Edimark
12 collaboration(s)
Dernière en 2023
Abbvie
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
EXCALIBER-RRMM: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Essai Clinique (Celgene)   12 mars 2024
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Annals of hematology   06 mars 2024
Leucémie lymphoïde chronique chez les moins de 30 ans
Edimark   28 février 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica   22 février 2024
DALY 2-EU: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
Essai Clinique (Miltenyi Biomedicine GmbH)   31 janvier 2024
BRUIN-MCL-321: A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
RAVEN: Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Essai Clinique (CHU Clermont-Ferrand)   08 janvier 2024